History of the World Allergy Organization: In 1951, the leaders in allergy from all
over the world came together to form the International Association of Allergology
and Clinical Immunology (IAACI). For the next 60 years, the allergy world converged
at the IAACI triennial meetings, which became biennial in 2003. The international
meetings, originally named the International Congress of Allergology and Clinical
Immunology (ICACI), are now the World Allergy Congress (WAC) hosted by the World Allergy
Organization (WAO). Everyone who has aspired to have worldwide recognition has played
a part in IAACI-WAO. The History of the World Allergy Organization traces the global
arc of the allergy field over the past 60 years.
The current officers of WAO elected to focus on this rich history, inviting prominent
leaders who are interested in being part of this history project to write about their
time with IAACI-WAO. This series will be presented in Cancún, México, as part of the
XXII World Allergy Congress (December 4-8, 2011). Leading up to the Congress in Cancún,
the World Allergy Organization Journal is presenting segments of the History as part
of the “Notes of Allergy Watchers Series.” Please enjoy.
—Michael A. Kaliner, MD
Historian and Past President (2006–2007)
World Allergy Organization
My own golden anniversary of 50 years in allergy coincides with the World Allergy
Organization’s (WAO’s) anniversary of 60 years of service to the specialty, and my
good fortune of being in the right place at the right time eventually led to the honor
of being elected President of the organization!
A NEW IMMUNOGLOBULIN ISOTYPE
In 1961, after 3 years at medical school, I had a holiday job at the Department of
Clinical Chemistry at the University Hospital in Uppsala working as a laboratory technician.
Uppsala has a very good tradition in the field of separation and characterization
of serum components, and I was asked to establish immunoelectrophoresis for characterization
of immunoglobulins and to study sera from patients with suspected immunological diseases.
A research group was then formed with the aim to isolate and characterize human immunoglobulins.
My colleague Hans Bennich was interested in the isolation and characterization of
human immunoglobulins, which included fragmentation with reduction/alkylation and
digestion by proteolytic enzymes. I raised antisera in rabbits to identify the various
fragments but also to set up immunoassays to characterize and quantitate the 3 known
immunoglobulin classes and their constituents, to support clinical investigations
of patients with suspected disturbances in this area, for example, immune deficiencies
and multiple myeloma.
In June of 1965, I found a myeloma protein where I could not identify the isotype.
It was an immunoglobulin with lambda light chains, unique antigens on the Fc fragment,
and a molecular weight in the order of 200,000 daltons, indicating that it represented
a new immunoglobulin isotype, which we provisionally called IgX. A hemagglutination
technique for diagnosis of pregnancy was developed for IgX, and in January 1967, IgX
was detected in serum of healthy individuals, thus fulfilling all the criteria for
a new immunoglobulin isotype. We provisionally designated this isotype by the initials
of the individual from which it was derived, IgND. As a result, the finding of increased
levels of IgND in allergic asthma and the development with Leif Wide of the test for
IgND antibodies to common allergens, RAST, were finalized and published. Interestingly,
these 2 approaches to describe serological events in allergy are still the basis of
in vitro diagnosis of IgE-mediated allergy.
During 1966, much effort was invested in understanding IgX. A collaboration was started
with Dennis Stanworth from Birmingham, United Kingdom, who had spent a lot of time
characterizing reaginic activity to horse dander allergen by the Prausnitz–Küstner
test. We aimed to test if IgX could block the P–K reaction, which was indeed the case,
and later to characterize the structure responsible for this activity, which was found
to be the Fc fragment.
From the fall of 1966, we had close contacts with D. S. Rowe, then at the World Health
Organization International Reference Centre for Immunoglobulins in Lausanne. We sent
him purified IgND immunoglobulin, fragments of IgND, and antisera specific for the
2 antigenic epitopes we had found on the Fc fragment, and he was able to confirm our
findings.
In 1966–1967, Kimishige Ishizaka and Teruko Ishizaka, then in Denver, had published
their findings on γE, reporting that their anti-γE could block the P–K reaction with
ragweed allergen and that when injected in the skin, it gave an erythema, hence the
“E.” Early in 1967, we sent a mail informing them of our finding of IgND and invited
them to a comparison with their γE. When it was found, and confirmed, that their anti-γE
reacted with isolated IgND and that anti-IgND inhibited the reaginic activity of their
γE-containing fractions, contacts with the World Health Organization were intensified.
In February 1968, a workshop was held at the Reference Centre in Lausanne with Kimishige
Ishizaka representing the γE leg and Hans Bennich and I the IgND leg of what was then,
for the first time, officially accepted as a new class of human immunogloblins, designated
IgE.1
NEW EXPERIENCES IN NATIONAL AND REGIONAL ALLERGY SOCIETIES
Because our initial findings on IgND were published in the Lancet, the message spread
quickly (Fig. 1). In 1968, I participated in my first congress of the European Academy
of Allergology and Clinical Immunology (EAACI) in Florence, Italy. In 1969, we presented
our data at the Royal Society of Medicine in London invited by J. L. Turk, and the
same year we visited for the first, of many times, Kimishige Ishizaka and Teruko Ishizaka
in Denver. In 1972, Sheldon C. Siegel invited me to my first annual meeting of the
American Academy of Allergy and Immunology, nowadays the American Academy of Allergy
Asthma and Immunology (AAAAI), held in San Francisco in 1972, to present our findings.
At the meeting, the Academy kindly nominated me as International Fellow, the first
appreciation I had the pleasure of receiving from an allergy society!
FIGURE 1
Gunnar Johansson and Hans Bennich in a laboratory demonstrating the washing of particles
in a centrifuge, circa. 1967. Reprinted from Johansson2 with permission from Elsevier.
During the 1970s, I spent time with I. Leonard Bernstein at the University of Cincinnati
as visiting professor, and I was invited several times to the United States, where
I enjoyed visiting many of the very best scientists and research centers in the field
of allergy and immunology—K. Frank Austen and Albert L. Sheffer in Boston; Philip
S. Norman and Lawrence Lichtenstein in Baltimore; John A. Anderson in Detroit; Roy
Patterson in Chicago and Gerald J. Gleich at the Mayo Clinic. Interestingly, all except
one of those notable individuals became President of AAAAI.
In the late 1970s, I was approached by Bengt Samuelsson, then Rector of the Karolinska
Institute, and invited to apply for a position as Professor of Clinical Immunology,
at the Karolinska Institute, combined with being Head of the Department of Clinical
Immunology, at the Karolinska Hospital. I accepted, of course, and started my work
in the summer of 1980. Since this was a new discipline at Karolinska I had to build
up the organization from scratch. It is not so easy to handle people, equipment, money,
and politicians when your experience is based on immunizing rabbits and performing
immunochemical laboratory bench work. In addition to building up a Department of Clinical
Immunology, I was also involved in administration within the Karolinska Hospital.
During 1984–1989, and as one of the Chief Physicians, I was responsible for the hospital’s
obligations to all clinical research. That was an interesting time that gave me a
lot of experience, as were the 6 years in the scientific committee of the H.R.H. Queen
Silvia of Sweden Foundation for Research on Children’s Handicap.
I had the pleasure of working as President of the Swedish Association of Allergology
(SFFA), and when I was elected a member of the Executive Committee of the European
Academy of Allergy and Immunology (EAACI) and in 1992 became President of EAACI, this
experience was very useful. We updated the infrastructure of EAACI, engaged a professional
executive office, introduced individual memberships, made a deal with the publishers
of Allergy to make it the official journal of EAACI, and negotiated a long-term sponsor
agreement with a group of companies, the so-called Founder Sponsors. When my 10 years
as Editor-in-Chief of Allergy expired in 2002, it was a pleasure to hand over the
responsibility to Jean Bousquet of Montpellier.
A NEW GLOBAL STRATEGY FOR AN INTERNATIONAL ALLERGY ORGANIZATION
As my term of office in EAACI ended in 1997, I had the pleasure of being nominated
President of the International Association of Allergology and Clinical Immunology
(IAACI). Again, it was time for an update. We held a strategic planning session in
Saltsjöbaden near Stockholm, where I worked for the first time with Karen Henley Davies,
the newly appointed Global Projects Director for WAO, who from then on provided essential
Europe-based support for my presidency. During a premeeting discussion with Rick Iber,
IAACI Executive Director, in the kitchen of the hotel, our first major idea was to
recommend a change of the name of the organization to make it stand out among the
many similar organizations relating to allergy and clinical immunology. We needed
a name to reflect the new overarching role that the organization needed to take on
if it was to survive in the global environment and to take responsibility for communication
within the world of allergy. Karen and I came up with the name World Allergy Organization
(WAO), which was proposed to the Executive Committee, meeting with great enthusiasm
from some and with great caution by others! There was some questioning to start with
whether it was too close to World Health Organization, I didn't think so. And it fit
very well with our ideas to save the IAACI and move in a different direction by determining
what really was needed in our specialty at a global level. There are so many allergy
societies, and we needed to take on a clear and necessary role to justify our existence.
Much discussion ensued on whether the name should be World Allergology Organization
but doubters were persuaded that World Allergy Organization would enable us to cover
many more issues relating to allergic disease that those relating purely to the clinical
practice of the specialty. It was also agreed, although with reservations, that Clinical
Immunology could be omitted from the new name.
At that time, IAACI was rather small, built on personal contacts and friends, not
really taking responsibility for anything like education, communication, or political
issues. The idea with WAO was to be the opposite, to really have representation from
all over the world, and to make sure that the various national societies did join
so that we had the possibility of communicating with them. I still think that this
is very very important for allergy as a specialty because there remains a big risk
that it will be pushed into a corner by respiratory physicians, laboratory doctors,
dermatologists, pediatricians and so forth—all of whom think that allergy is a little
part of their business, but all of whom really worry about everything else but allergy.
At that time, the international members were there for geographical balance, but it
didn’t mean that one was working actively on some kind of communication or collaboration
with, for example, the Japanese Society of Allergology or the AAAAI. The old Europeans
were in charge and did what they wished to do, and while that might have been great
in the beginning, changes were vital for the future of the organization. We brought
in many new young people who were really prepared to work hard for the organization
instead of using it as a personal career step.
I was pleased to have the opportunity of introducing new programs, such as the educational
program, Global Resources in Allergy (GLORIA). This started as collaboration with
EAACI to disseminate their new guidelines on the management of allergic rhinitis and
then expanded to incorporate all aspects of allergic disease. GLORIA is now a comprehensive
series of 14 lectures on major topics in allergy that can be downloaded from the WAO
Web site (www.worldallergy.org). The program was originally sponsored by a group of
industry supporters enabling lectures to be given around the world, and local faculties
were trained to present the lectures to educate the primary care doctors in their
countries.
This mirrored the new kind of sponsorship, the “Founder Sponsors” group, which I had
introduced for the EAACI. Before this arrangement, the individual in charge of the
congress, the local chair, was able to run the congress as a private business and
to make special deals with individual companies. I thought that was unfair. If companies
sponsor the congress, then the society behind the congress should have access to any
money left over after the congress and to make it available for educational projects
or grants for young people or whatever other local needs had been identified. After
the 1995 meeting, I sat down with Ulf Säther at Pharmacia Diagnostics and convinced
them that this was a good idea, and then we tried to recruit other companies that
were prepared to be involved and to sponsor 3 congresses in a row at a given amount
of money. For that commitment, they would have clearly defined sponsorship benefits
to look forward to like a seminar, advertisements, and a hospitality room. To start
with, this was a very difficult discussion because they hadn’t all heard about it
and they didn't all like it; they thought they should be allowed to handle this individually,
but after several meetings, the idea was accepted and liked and became a successful
long-term commitment. Adopting a similar policy for GLORIA ensured that no one company
dominated and no conflict of interest would exist.
We also initiated the WAO Web site (www.worldallergy.org). This was originally trademarked
as GAIN—the Global Allergy Information Network, with the aim to create links between
all the reputable Web sites on allergy and to provide original information and education
where it was not already available from other sites. This attracted development funding
from Aventis, with the personal support of Keith Allan, who has continued to support
the site as he has moved within the pharmaceutical industry over the years!
A NEW CENTURY WITH INCREASED ALLERGY PREVALENCE
At “my congress,” organized magnificently by Connie Katelaris, in Sydney in 2000,
I became past president (Fig. 2). I continued to work with numerous WAO projects,
most notably coediting, with Tari Haahtela, the Prevention of Allergy and Allergic
Asthma book that had started as a collaboration with World Health Organization but
then became a WAO standalone project after a number of changes in WHO policy relating
to their relationships with not-for-profit organizations.3 I was then invited to form
the WAO Nomenclature Committee to agree a revised nomenclature for allergy, endorsed
by EAACI and WAO and its 70 member societies. You can’t communicate with people unless
you have one and the same language. If someone is talking about atopy as clinical
symptoms, and someone else is using atopy as a definition of the genetic familiar
tendency to become IgE sensitized, of course they have problems understanding each
other. Considerable work ensued in promoting the new nomenclature to encourage its
uptake, including translations and publications in WAO Member Society journals, and
hopefully, we now better understand each other, and our field of expertise can continue
to flourish and develop.4
FIGURE 2
Cover of the final program of the XVII International Congress of Allergology and Clinical
Immunology in Sydney, Australia, in 2000.
WAO is doing fine and is living up to our expectations, thanks to preceding presidents
like Terumasa Miyamoto of Tokyo and Alberto Oehling of Pamplona, and I am delighted
at the way the organization has continued to grow under the direction of my presidential
successors. The organization has managed to establish positive relationships with
many important national allergy societies, but there is still a lot to do. There are
still aspects of allergy that need to be further investigated at a scientific level.
Allergy is very important because it is part of many many clinical specialties and
because it is a special kind of disorder with special mechanisms requiring special
approaches to treatment and diagnosis. The major problem is that the prevalence of
allergic disease is so high and in many areas of the world is increasing. There are
so many millions of patients who need access to a physician with some knowledge about
allergy so that they can be referred to the right kind of specialist, and this remains
one of our major challenges.
Much has happened in the past 60 years, but there is still much to do!